Autism-Associated DNA Methylation at Birth From Multiple Tissues Is Enriched for Autism Genes in the Early Autism Risk Longitudinal Investigation
Copyright © 2021 Bakulski, Dou, Feinberg, Aung, Ladd-Acosta, Volk, Newschaffer, Croen, Hertz-Picciotto, Levy, Landa, Feinberg and Fallin..
Background: Pregnancy measures of DNA methylation, an epigenetic mark, may be associated with autism spectrum disorder (ASD) development in children. Few ASD studies have considered prospective designs with DNA methylation measured in multiple tissues and tested overlap with ASD genetic risk loci. Objectives: To estimate associations between DNA methylation in maternal blood, cord blood, and placenta and later diagnosis of ASD, and to evaluate enrichment of ASD-associated DNA methylation for known ASD-associated genes. Methods: In the Early Autism Risk Longitudinal Investigation (EARLI), an ASD-enriched risk birth cohort, genome-scale maternal blood (early n = 140 and late n = 75 pregnancy), infant cord blood (n = 133), and placenta (maternal n = 106 and fetal n = 107 compartments) DNA methylation was assessed on the Illumina 450k HumanMethylation array and compared to ASD diagnosis at 36 months of age. Differences in site-specific and global methylation were tested with ASD, as well as enrichment of single site associations for ASD risk genes (n = 881) from the Simons Foundation Autism Research Initiative (SFARI) database. Results: No individual DNA methylation site was associated with ASD at genome-wide significance, however, individual DNA methylation sites nominally associated with ASD (P < 0.05) in each tissue were highly enriched for SFARI genes (cord blood P = 7.9 × 10-29, maternal blood early pregnancy P = 6.1 × 10-27, maternal blood late pregnancy P = 2.8 × 10-16, maternal placenta P = 5.6 × 10-15, fetal placenta P = 1.3 × 10-20). DNA methylation sites nominally associated with ASD across all five tissues overlapped at 144 (29.5%) SFARI genes. Conclusion: DNA methylation sites nominally associated with later ASD diagnosis in multiple tissues were enriched for ASD risk genes. Our multi-tissue study demonstrates the utility of examining DNA methylation prior to ASD diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in molecular neuroscience - 14(2021) vom: 03., Seite 775390 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bakulski, Kelly M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autism spectrum disorder |
|---|
| Anmerkungen: |
Date Revised 21.01.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fnmol.2021.775390 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334356512 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334356512 | ||
| 003 | DE-627 | ||
| 005 | 20231225223534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fnmol.2021.775390 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1114.xml |
| 035 | |a (DE-627)NLM334356512 | ||
| 035 | |a (NLM)34899183 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bakulski, Kelly M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Autism-Associated DNA Methylation at Birth From Multiple Tissues Is Enriched for Autism Genes in the Early Autism Risk Longitudinal Investigation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.01.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Bakulski, Dou, Feinberg, Aung, Ladd-Acosta, Volk, Newschaffer, Croen, Hertz-Picciotto, Levy, Landa, Feinberg and Fallin. | ||
| 520 | |a Background: Pregnancy measures of DNA methylation, an epigenetic mark, may be associated with autism spectrum disorder (ASD) development in children. Few ASD studies have considered prospective designs with DNA methylation measured in multiple tissues and tested overlap with ASD genetic risk loci. Objectives: To estimate associations between DNA methylation in maternal blood, cord blood, and placenta and later diagnosis of ASD, and to evaluate enrichment of ASD-associated DNA methylation for known ASD-associated genes. Methods: In the Early Autism Risk Longitudinal Investigation (EARLI), an ASD-enriched risk birth cohort, genome-scale maternal blood (early n = 140 and late n = 75 pregnancy), infant cord blood (n = 133), and placenta (maternal n = 106 and fetal n = 107 compartments) DNA methylation was assessed on the Illumina 450k HumanMethylation array and compared to ASD diagnosis at 36 months of age. Differences in site-specific and global methylation were tested with ASD, as well as enrichment of single site associations for ASD risk genes (n = 881) from the Simons Foundation Autism Research Initiative (SFARI) database. Results: No individual DNA methylation site was associated with ASD at genome-wide significance, however, individual DNA methylation sites nominally associated with ASD (P < 0.05) in each tissue were highly enriched for SFARI genes (cord blood P = 7.9 × 10-29, maternal blood early pregnancy P = 6.1 × 10-27, maternal blood late pregnancy P = 2.8 × 10-16, maternal placenta P = 5.6 × 10-15, fetal placenta P = 1.3 × 10-20). DNA methylation sites nominally associated with ASD across all five tissues overlapped at 144 (29.5%) SFARI genes. Conclusion: DNA methylation sites nominally associated with later ASD diagnosis in multiple tissues were enriched for ASD risk genes. Our multi-tissue study demonstrates the utility of examining DNA methylation prior to ASD diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a autism spectrum disorder | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a cord blood | |
| 650 | 4 | |a epidemiology | |
| 700 | 1 | |a Dou, John F |e verfasserin |4 aut | |
| 700 | 1 | |a Feinberg, Jason I |e verfasserin |4 aut | |
| 700 | 1 | |a Aung, Max T |e verfasserin |4 aut | |
| 700 | 1 | |a Ladd-Acosta, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Volk, Heather E |e verfasserin |4 aut | |
| 700 | 1 | |a Newschaffer, Craig J |e verfasserin |4 aut | |
| 700 | 1 | |a Croen, Lisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Hertz-Picciotto, Irva |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Susan E |e verfasserin |4 aut | |
| 700 | 1 | |a Landa, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Feinberg, Andrew P |e verfasserin |4 aut | |
| 700 | 1 | |a Fallin, Margaret D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in molecular neuroscience |d 2008 |g 14(2021) vom: 03., Seite 775390 |w (DE-627)NLM183921038 |x 1662-5099 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g day:03 |g pages:775390 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fnmol.2021.775390 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |b 03 |h 775390 | ||